Age-Related Macular Degeneration (AMD) News This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

FDA Approves Genentech ’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema Approval is based on two Phase III studies demonstrating early and sustained vision improvements that were... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 26, 2023 Category: Drugs & Pharmacology Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Basel, 19 October 2023Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecen...
Source: Roche Media News - October 19, 2023 Category: Pharmaceuticals Source Type: news

[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good sales growth despite decline in demand for COVID-19 products
Groupsales grow by 1%1at constant exchange rates (CER) in the first nine months, showing a strong increase of 7% in the third quarterExcluding COVID-19 products,Group salesincrease by 9%Pharmaceuticals Division sales grow by 9%, driven by continued high demand for newer medicinesDiagnostics Division ’s base businessincreases by 7%;overall divisional sales are down 18% due to a surge in demand for COVID-19 tests in 2022Highlightsin the third quarter of 2023:EU approval ofEvrysdifor babies under two months old with spinal muscular atrophyFirst approval of subcutaneous form of cancer immunotherapyTecentriqPositive phase III...
Source: Roche Investor Update - October 19, 2023 Category: Pharmaceuticals Source Type: news

Faricimab Efficacy, Safety Hold Up in Real-World Study Faricimab Efficacy, Safety Hold Up in Real-World Study
A real-world study of faricimab in neovascular age-related macular degeneration showed visual and anatomical improvement in line with phase 3 trials in treatment-naive and previously treated eyes.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 12, 2023 Category: Consumer Health News Tags: Ophthalmology News Source Type: news

Eye Specialists Miss Mental Health Issues Linked to AMD Eye Specialists Miss Mental Health Issues Linked to AMD
Patients with age-related macular degeneration are known to experience high rates of depression and anxiety, but clinicians often miss the problems, prompting a call for a consensus statement.Medscape Medical News (Source: Medscape Psychiatry Headlines)
Source: Medscape Psychiatry Headlines - October 10, 2023 Category: Psychiatry Tags: Ophthalmology News Source Type: news

Roche ’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies
Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studiesRegulatory applications for Vabysmo in RVO are under review by health authorities around the world; if approved, RVO would be the third indication in addition to nAMD and DMEVabysmo is the first and only treatment that targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditionsBasel, 10 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline long-term results from the global phase III BALATON and COMINO studies, evaluating extended tre...
Source: Roche Media News - October 10, 2023 Category: Pharmaceuticals Source Type: news

Roche ’s Vabysmo maintained vision improvements with extended treatment intervals up to four months for people with retinal vein occlusion (RVO) in phase III studies
Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous studiesRegulatory applications for Vabysmo in RVO are under review by health authorities around the world; if approved, RVO would be the third indication in addition to nAMD and DMEVabysmo is the first and only treatment that targets and inhibits two signalling pathways linked to a number of vision-threatening retinal conditionsBasel, 10 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline long-term results from the global phase III BALATON and COMINO studies, evaluating extended tre...
Source: Roche Investor Update - October 10, 2023 Category: Pharmaceuticals Source Type: news

Exudative Age-Related Macular Degeneration: The Advent of Anti-VEGF Agents Exudative Age-Related Macular Degeneration: The Advent of Anti-VEGF Agents
Thomas Ciulla, MD, discusses the clinical transition from therapeutically limited laser-based therapies to the introduction of anti-VEGF drugs.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 18, 2023 Category: Consumer Health News Tags: Ophthalmology MDAngle Source Type: news

Exudative Macular Degeneration: Patient's Goals Shape Care Exudative Macular Degeneration: Patient's Goals Shape Care
Vaidehi Dedania, MD, describes how an encounter with a patient with exudative age-related macular degeneration shaped her treatment approach.Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 18, 2023 Category: Consumer Health News Tags: Ophthalmology MDAngle Source Type: news

Macular degeneration research grows human cells in artificial eye
Researchers hope it could eventually lead to new ways of treating age-related macular degeneration. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - September 13, 2023 Category: Consumer Health News Source Type: news

DR MARTIN SCURR: Simple steps to help ward off sight-loss as you age
DR MARTIN SCURR: Age-related macular degeneration (AMD) is commonly diagnosed in older people and is, understandably, a source of anxiety. (Source: the Mail online | Health)
Source: the Mail online | Health - September 11, 2023 Category: Consumer Health News Source Type: news

Safety of Recent Ophthalmic Drugs and Devices for Wet AMD Safety of Recent Ophthalmic Drugs and Devices for Wet AMD
What do we currently know about the safety of recently approved drugs and devices for the treatment of neovascular age-related macular degeneration?Current Opinion in Ophthalmology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 6, 2023 Category: Consumer Health News Tags: Ophthalmology Journal Article Source Type: news

'I’m a nutritionist — here are my top three ingredients to protect my eye health'
A nutritionist recommends eye-friendly ingredients you should be adding to your shopping trolley in order to stave off problems, ranging from cataracts to age-related macular degeneration. (Source: Daily Express - Health)
Source: Daily Express - Health - August 30, 2023 Category: Consumer Health News Source Type: news

Induced Pluripotent Stem Cells For Age-Related Macular Degeneration
Induced pluripotent stem cells show great promise for age-related macular degeneration, as revealed by recent research published in the New England Journal of Medicine. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - August 22, 2023 Category: Pharmaceuticals Authors: William A. Haseltine, Contributor Tags: Healthcare /healthcare Innovation /innovation business pharma & standard Source Type: news

Why This Regeneron Approval'Could Not Come Soon Enough '
Shares of REGN stock jumped Monday after the Food and Drug Administration approved Regeneron Pharmaceuticals' (REGN) high-dose Eylea following a delay this summer. Late Friday, the FDA signed off on an 8-milligram dose of Eylea to treat three eye diseases: wet age-related macular degeneration,…#eylea #fda #regeneron #pipersandler #christopherraymond #novartis #vabysmo #rbccapitalmarkets #brianabrahams #standardeylea (Source: Reuters: Health)
Source: Reuters: Health - August 22, 2023 Category: Consumer Health News Source Type: news